Evidence for Predictive Validity of Remission on Long-Term Outcome in Rheumatoid Arthritis: A Systematic Review

被引:79
作者
van Tuyl, Lilian H. D. [1 ]
Felson, David T. [2 ]
Wells, George [3 ]
Smolen, Josef [4 ]
Zhang, Bin [2 ]
Boers, Maarten
机构
[1] Vrije Univ Amsterdam Med Ctr, Dept Rheumatol, NL-1007 MB Amsterdam, Netherlands
[2] Boston Univ, Sch Med, Boston, MA 02118 USA
[3] Univ Ottawa, Ottawa, ON, Canada
[4] Med Univ Vienna, Vienna, Austria
关键词
MODIFYING ANTIRHEUMATIC DRUGS; RADIOGRAPHIC PROGRESSION; SUSTAINED REMISSION; CLINICAL REMISSION; JOINT DAMAGE; RECEPTOR INHIBITION; AMERICAN-COLLEGE; RANDOMIZED-TRIAL; DOUBLE-BLIND; DISEASE;
D O I
10.1002/acr.20021
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objective. Remission is rapidly becoming a key end point in rheumatoid arthritis (RA) clinical trials, but its definition is not satisfactory. Although it is generally believed that achieving a state of remission will lead to better structural outcome, this has not been studied systematically. As part of an undertaking to redefine remission, the current review describes the relationship between remission and long-term structural outcome. Methods. A systematic literature search of PubMed, EMBase, and The Cochrane Library intersected 3 groups of terms: RA, remission, and long-term outcome. The search identified 1,138 records, of which 14 were relevant to the research question. Results. All of the studies included in this review showed a relationship between remission and long-term structural damage or disability. Patients that achieved a state of remission, defined in various ways, showed less deterioration of function and radiographic progression compared with patients who did not reach a state of remission. Conclusion. Patients who achieved a state of remission were less likely to show deterioration of function and radiographic progression compared with patients who did not reach a state of remission.
引用
收藏
页码:108 / 117
页数:10
相关论文
共 33 条
[1]
Remission and active disease in rheumatoid arthritis - Defining criteria for disease activity states [J].
Aletaha, D ;
Ward, MM ;
Machold, KP ;
Nell, VPK ;
Stamm, T ;
Smolen, JS .
ARTHRITIS AND RHEUMATISM, 2005, 52 (09) :2625-2636
[2]
Rheumatoid Arthritis Joint Progression in Sustained Remission Is Determined by Disease Activity Levels Preceding the Period of Radiographic Assessment [J].
Aletaha, D. ;
Funovits, J. ;
Breedveld, F. C. ;
Sharp, J. ;
Segurado, O. ;
Smolen, J. S. .
ARTHRITIS AND RHEUMATISM, 2009, 60 (05) :1242-1249
[3]
An Explanation for the Apparent Dissociation Between Clinical Remission and Continued Structural Deterioration in Rheumatoid Arthritis [J].
Brown, A. K. ;
Conaghan, P. G. ;
Karim, Z. ;
Quinn, M. A. ;
Ikeda, K. ;
Peterfy, C. G. ;
Hensor, E. ;
Wakefield, R. J. ;
O'Connor, P. J. ;
Emery, P. .
ARTHRITIS AND RHEUMATISM, 2008, 58 (10) :2958-2967
[4]
Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference [J].
Bruynesteyn, K ;
van der Heijde, D ;
Boers, M ;
Saudan, A ;
Peloso, P ;
Paulus, H ;
Houben, H ;
Griffiths, B ;
Edmonds, J ;
Bresnihan, B ;
Boonen, A ;
van der Linden, S .
ARTHRITIS AND RHEUMATISM, 2002, 46 (04) :913-920
[5]
Radiological damage in patients with rheumatoid arthritis on sustained remission [J].
Cohen, G. ;
Gossec, L. ;
Dougados, M. ;
Cantagrel, A. ;
Goupille, P. ;
Daures, J. P. ;
Rincheval, N. ;
Combe, B. .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (03) :358-363
[6]
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial [J].
Emery, P. ;
Keystone, E. ;
Tony, H. P. ;
Cantagrel, A. ;
van Vollenhoven, R. ;
Sanchez, A. ;
Alecock, E. ;
Lee, J. ;
Kremer, J. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) :1516-1523
[7]
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial [J].
Emery, Paul ;
Breedveld, Ferdinand C. ;
Hall, Stephen ;
Durez, Patrick ;
Chang, David J. ;
Robertson, Deborah ;
Singh, Amitabh ;
Pedersen, Ronald D. ;
Koenig, Andrew S. ;
Freundlich, Bruce .
LANCET, 2008, 372 (9636) :375-382
[8]
AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY DEFINITION OF IMPROVEMENT IN RHEUMATOID-ARTHRITIS [J].
FELSON, DT ;
ANDERSON, JJ ;
BOERS, M ;
BOMBARDIER, C ;
FURST, D ;
GOLDSMITH, C ;
KATZ, LM ;
LIGHTFOOT, R ;
PAULUS, H ;
STRAND, V ;
TUGWELL, P ;
WEINBLATT, M ;
WILLIAMS, HJ ;
WOLFE, F ;
KIESZAK, S .
ARTHRITIS AND RHEUMATISM, 1995, 38 (06) :727-735
[9]
Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study [J].
Hafstroem, I. ;
Albertsson, K. ;
Boonen, A. ;
van der Heijde, D. ;
Landewe, R. ;
Svensson, B. .
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (04) :508-513
[10]
Remission by composite scores in rheumatoid arthritis: are ankles and feet important? [J].
Kapral, Theresa ;
Dernoschnig, Florian ;
Machold, Klaus P. ;
Stamm, Tanja ;
Schoels, Monika ;
Smolen, Josef S. ;
Aletaha, Daniel .
ARTHRITIS RESEARCH & THERAPY, 2007, 9 (04)